Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital tools

Alternative Approaches to Personalized Medicine in Oncology

Laura Towart, Founder & CEO of My Personal Therapeutics, discusses her company’s approach to precision medicine, the barriers patients with cancer face when trying to access personalized treatments, and how...

Impetus Digital

Reimagining Healthcare Using Mobile Health Technologies

Kim Shah, CEO of KnowYourMeds, explores digital health, AI, telemedicine, health literacy, and how to ensure a safe return to work amidst the ongoing COVID-19 pandemic. We also dive into...

Impetus Digital

- PMLiVE

BMS links up with Molecular Templates for oncology research collaboration

Deal could be worth up to $1.3bn in milestone payments

- PMLiVE

Mistrust in medical research: a patient perspective

The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...

Blue Latitude Health

- PMLiVE

Real-world evidence: breaking boundaries in rare disease

Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Blue Latitude Health

- PMLiVE

The heavy toll of COVID-19 on cancer patients

We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Blue Latitude Health

Future-Proofing Healthcare and Medicine

Bogi Eliasen, Director of Health at Copenhagen Institute for Futures Studies, discusses the future of genomics, personalized health, healthcare data, digital health, and more.

Impetus Digital

- PMLiVE

Lilly partners with Merus on development of bispecific antibodies for cancer

As part of the deal, Merus could receive a total of up to around $1.6bn for three products

- PMLiVE

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

Investigational PD-1 inhibitor is being studied in mismatch repair-deficient solid tumours

- PMLiVE

bluebird bio to separate oncology and rare diseases units

New oncology company will be led by current bluebird bio CEO Nick Leschly

Delphi Technique Virtual Co-creation: A Customer Story

How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints.

Impetus Digital

- PMLiVE

Kite and Oxford BioTherapeutics sign oncology research pact

Agreement will focus on five novel drug targets across a range of indications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links